Welcome to Money May's Vignettes, where we share some of the most interesting extracts from our episodes.

These bite-sized minisodes, each less than 10 minutes long, complement our long-form features.

If you enjoy the following Money Maze vignette, please do share it on your social media media or give us a positive review on your preferred podcast app.

And to stay up to date, you're welcome to sign up to our newsletter, which is available via

money mazepodcast.com. Thank you. This episode is kindly brought to you by our sponsors,

Schroeder's, live trade by Bordeaux Index, and Vermont Watches.

Now, let's talk about genetics because I think, again, it would be fair to say that lots of people

have become more aware of the broad what happened when we started mapping the genomes. But you've got some

really interesting work that you've done. And when you mentioned the geographies, of course,

you mentioned Iceland, which most biotech companies or pharma companies wouldn't. In fact,

most companies period wouldn't have Iceland on their map. Tell us a little bit about how you're approaching genetics.

Iceland is a particularly important place in the field of human genetics.

The reason it is, Simon, is, as you know, Iceland is an isolated island in the middle of the North Atlantic.

And for hundreds and even thousands of years, there was very little trafficking of people on and off the island.

That created what we call a founder population.

And so the genetics on the island of Iceland make for a very interesting laboratory

to try and understand the genetic conditions that predispose people to disease or to a life

of good health.

That has been the main focus in our human genetics, has

occurred on the island of Iceland, through a company that we acquired in 2012 called Decode Genetics.

And so the beauty of a founder population like that is that if there are rare variants in an

individual's genome or gene profile that gives rise to a serious

...